Used in pharmaceutical research as a key intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. Its structure enables selective binding to cereblon, facilitating the degradation of disease-causing proteins. This makes it valuable in developing treatments for cancers such as multiple myeloma and other hematological malignancies. Also explored in the design of PROTACs (proteolysis-targeting chimeras) for its ability to link with target protein ligands, enhancing specificity and efficacy in drug development.